ICD therapy in RVOT-VT and early stage ARVD/C patients

Yoshiyasu Aizawa, Seiji Takatsuki, Keiichi Fukuda

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Implantable cardioverter-defibrillators (ICDs) improve the survival of patients with ischemic or non-ischemic cardiomyopathy and a reduced ejection fraction. However, the efficacy of ICD therapy in patients with right ventricular outflow tract ventricular tachycardia (RVOT-VT) and early stage arrhythmogenic right ventricular dysplasia / cardiomyopathy (ARVD/C) has not been well clarified. Although the prognosis of RVOT-VT is generally good, malignant forms of RVOT-VT resulting in polymorphic VT have been reported by several investigators. Radiofrequency catheter ablation is still effective in such patients, and thus an ICD implantation is usually not required. On the other hand, according to the current guidelines in patients with ARVD/C, an ICD implantation is recommended for secondary prevention when the patients develop sustained VT or VF. An ICD implantation may also be considered for primary prevention in high-risk patients: extensive disease, family history of sudden cardiac death, or undiagnosed syncope. Since an ICD implantation in the early stage of ARVD/C is controversial, physicians should well consider its risks and benefits. Early intervention with ICD therapy in ARVD/C patients may reduce the arrhythmic death rate but increases the device related complications especially in younger patients.

Original languageEnglish
JournalJournal of Atrial Fibrillation
Issue number2
Publication statusPublished - 2014 Aug 1


  • Arrhythmogenic Right Ventricular Cardiomyopathy
  • Implantable Cardioverter-Defibrillator
  • Ventricular Tachycardia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'ICD therapy in RVOT-VT and early stage ARVD/C patients'. Together they form a unique fingerprint.

Cite this